Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

NCT02152982 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02152982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02152982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 15, 2014
Completion date
December 26, 2026
Enrollment
447 (actual)
Sites
391

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, gliosarcoma